Podcasts about idsa

Group A Streptococcus (GAS) is a common cause of pharyngitis, but deciding who should be tested and which testing method to use isn't always straightforward. In 2025, the Infectious Diseases Society of America (IDSA) released updated guidelines on Group A streptococcal pharyngitis, bringing renewed attention to diagnostic stewardship and the use of clinical scoring systems to help guide testing decisions. In this episode of Let's Talk Micro, Dr. Christopher Doern returns to the podcast to break down the updated IDSA guidelines and what they may mean for clinical practice. We discuss clinical scoring systems such as Centor and McIsaac, antigen testing, culture, molecular diagnostics, and point-of-care testing. We also explore turnaround time and cost considerations, GAS carriage and the interpretation of positive results, and how diagnostic decisions connect with antimicrobial stewardship. Tune in as we take a practical look at what's changing in Group A strep testing and how laboratories and clinicians can approach these updated recommendations. This podcast episode is sponsored by Cepheid. The views and opinions expressed by the interviewer in this interview are their own and do not necessarily reflect the position of Cepheid. Resources IDSA Clinical Practice Guideline Update on Group A Streptococcal (GAS) Pharyngitis: IDSA 2025 Group A Streptococcal Pharyngitis Guideline Current Laboratory and Point-of-Care Pharyngitis Diagnostic Testing and Knowledge Gaps: https://pubmed.ncbi.nlm.nih.gov/39688598/ Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Henry Masur, MD, Senior Investigator and Director, Critical Care Medicine Department, National Institutes of Health, MarylandCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link:⁠ ⁠ ⁠⁠https://forms.cloud.microsoft/r/eDjL4W5yVp or copy & paste into your browser).Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty report no relevant financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated, in accordance with ACCME requirements.Original Date: September 8, 2026End Date: September 8, 2027

Henry Masur, MD, Senior Investigator and Director, Critical Care Medicine Department, National Institutes of Health, MarylandCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link:⁠ ⁠ ⁠⁠https://forms.cloud.microsoft/r/eDjL4W5yVp or copy & paste into your browser).Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty report no relevant financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated, in accordance with ACCME requirements.Original Date: September 8, 2026End Date: September 8, 2027

Broadcast from KSQD, Santa Cruz on 9-03-2026: With CDC vaccine guidance politically contested, major medical societies (AAFP, AAP, ACOG, IDSA) issued their own recommendations through the Vaccine Integrity Project. Dr. Dawn recommends flu shots in October for peak Thanksgiving antibodies, high-dose flu vaccine (not adjuvanted) for frail seniors, and COVID/flu/RSV given at the same visit—except delay COVID vaccination four to six months after recent infection. Pregnant women should receive RSV vaccine at 32-36 weeks, and infants under eight months entering their first RSV season need vaccination if the mother wasn't vaccinated. RSV is one-time only for adults 75+, or for high-risk 50-74-year-olds. Measles is the most contagious human disease, transmissible through brief incidental contact (buses, taxis, carnival rides). Beyond acute mortality (one in 5,000 pre-vaccine), survivors face rare but catastrophic subacute sclerosing panencephalitis 10-40 years later—immune-mediated brain destruction comparable to Huntington's. Thirty percent of current outbreak cases are in adults reflecting decades of under-vaccination in certain communities, and pregnant unvaccinated mothers create a dangerous one-year window since the live vaccine cannot be given during pregnancy. Inlicitide (brand name Lipithandra) is the first oral PCSK9 inhibitor for LDL reduction, priced at $315/month versus $600 for the injectable version. Dr. Dawn positions it strictly as a treatment—not preventive—drug for patients who've had a heart attack or equivalent event and cannot achieve target LDL on statins alone, with prior authorization typically successful given documented disease. Updated cancer screening guidance from major societies: cervical cancer screening at 25 for HPV-vaccinated women (earlier if unvaccinated), annual mammograms from 45-54 then biennial, PSA screening starting at 50, and low-dose CT lung cancer screening at 50-80 for heavy smokers. Dr. Dawn pushes back on the 2018 Task Force downplaying of PSA screening, noting MRI-targeted transperineal biopsies have dramatically reduced false-positive complications. She also warns about rising male cancer diagnoses at later stages for stomach, lung, tongue, and throat cancers, and recommends the vinegar test for suspicious oral white spots. Parkinson's disease develops through a decades-long prodromal phase before motor symptoms appear—by tremor onset, at least half the substantia nigra neurons are dead. Four early warning signs: persistent loss of smell (90% of Parkinson's patients experience this up to 20 years before diagnosis; free scratch-and-sniff cards available from The Michael J. Fox Foundation), REM sleep behavior disorder (acting out dreams; 50-70% develop Parkinson's or Lewy body dementia within 5-10 years, 130-fold higher risk if over 50), chronic constipation (possibly linked to gut microbiome production of misfolded alpha-synuclein), and orthostatic hypotension. Available diagnostics include alpha-synuclein seed amplifier assay (CSF), skin biopsy, and DaTscan SPECT imaging (typically covered with "clinical uncertainty" documentation). A caller with insomnia asks about using vinegar to clean his new CPAP machine. Dr. Dawn recommends one part white vinegar to three parts warm water, then rinsing—or unscented Dr. Bronner's castile soap. She emphasizes avoiding bleach, alcohol, ammonia, scented soaps, and moisturizers, since mold prevention is the primary cleaning goal. Columbia University's STAR (Sperm Track and Recovery) AI system, inspired by astronomical star-detection algorithms, hunts vanishingly rare sperm in men with azoospermia by streaming semen through a hair-thin channel imaged 300 times per second. A robotic arm extracts flagged cells within milliseconds. Of 175 patients tested, 30% had recoverable sperm, and the system produced its first baby late last year for a couple with 20 years of infertility.

Meet the newest voices behind Let's Talk ID. Infectious disease physicians Kelly Cawcutt, MD, MS, FACP, FIDSA, FCCM, FSHEA, and Nico Cortes-Penfield, MD, FACP, FIDSA, join the podcast as co-hosts for episodes focused on research published in IDSA journals. In their first episode, they speak with Joy Juskowich, MD, and Arif Sarwari, MBA, MD, MSC, authors of a Clinical Infectious Diseases study on early transition from IV to oral antibiotics and discuss its implications for clinical practice. The study: https://academic.oup.com/cid/article/82/4/e674/8384448

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Infectologia, com foco em HIV, infecções por Clostridioides difficile, bacteremias por Staphylococcus aureus, profilaxia antifúngica em transplantes e resistência bacteriana. Falamos sobre o uso do lenacapavir em pessoas vivendo com HIV multiexperimentadas, a nova diretriz da AGA para infecção por C. difficile, as evidências que posicionam a cefazolina como alternativa às penicilinas antiestafilocócicas nas bacteremias por MSSA, as recomendações da IDSA para profilaxia de aspergilose invasiva em transplantados e as opções terapêuticas para infecções por bacilos Gram-negativos produtores de metalo-beta-lactamases (MBL).Leia na íntegra os artigos mencionados hoje:Lenacapavir como opção para o tratamento de PVHIV multiexperimentadosInfecção por Clostridioides difficile: nova diretriz da AGA 2026Eficácia e segurança da cefazolina no tratamento de bacteremias por MSSAProfilaxia de aspergilose invasiva em transplantes: o que diz a diretriz IDSA?Infecções por bacilos Gram-negativos produtores de MBL: aztreonam-avibactam ou ceftazidima-avibactam + aztreonam?

This episode features Prof. Cynthia L. Sears, MD from the Johns Hopkins University School of Medicine and the Bloomberg School of Public Health (USA), speaking about both biofilms and specific gut microorganisms that may contribute to colorectal cancer development. Initially, Prof. Sears became interested in enterotoxigenic Bacteroides fragilis in connection with colon cancer. Further investigation found complex biofilms with multiple bacteria fixed to the surface of the tumor. The biofilms were shown to be oncogenic, and they reassembled very quickly after antibiotic treatment. Interestingly, the biofilms were found to have C. difficile. A subset of the biofilms have a dominant amount of Fusobacterium, and the latest work shows that these bacteria are associated with advancing cancer, stage 2 or beyond. These bacteria and/or biofilms don't necessarily trigger the onset of mutations that lead to colon cancer, but they accelerate tumor growth. Over time, the gut microbiota may be perturbed in various ways (including by antibiotics), allowing the organisms to create a niche for themselves that ultimately harms the colonic epithelial cells. Prof. Sears is optimistic about prevention strategies for colorectal cancer, such as a tool that helps predict risk in younger populations. Targeted prebiotics, too, show promise for encouraging the growth of beneficial bacteria that prevent the oncogenic species from finding a niche. Episode abbreviations and links: 2014 review by Sears and Garrett on the role of microbes in colon cancer: Microbes, Microbiota, and Colon Cancer One of the landmark 2012 papers linking Fusobacterium nucleatum to colorectal cancer: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma Examination of biofilms on colon cancer polyps: Epidemiology of bacterial biofilms on polyps and normal tissues in a screening colonoscopy cohort Association of Fusobacterium with advancing (stage 2) colorectal cancer: Tumor-Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer Paper showing genotoxic microbes increasing colon tumor burden: Combining genotoxic gut bacterial strains increases tumor burden and accelerates onset in a germ-free mouse model of colon carcinogenesis About Prof. Cynthia L. Sears, MD: Cynthia L. Sears, M.D. is Professor of Medicine, Oncology and Molecular Microbiology and Immunology at the Johns Hopkins University School of Medicine and the Bloomberg School of Public Health. Through her work as an infectious diseases specialist, she studies how bacteria and the microbiome impact gut diseases, particularly human colon cancer. She has long been an active member of the Infectious Diseases Society of America (IDSA), serving as President of IDSA in 2019, is an AAAS Fellow and is currently Editor-in-Chief of The Journal of Infectious Diseases, the flagship journal of the IDSA.

I almost finished my July 4th call week. Good news! Portland did not blow its face off this year. No open globes, no eyelid lacerations, no thermal injuries, no sclopetaria. Bad news: a Friday holiday means every unanswered call from every patient at every one of our offices lands on the on-call doctor, and I earned every one of them. I walk through three cases. First, a cataract surgery my partner had to abort mid-procedure because the patient had six clock hours of zonule laxity. I explain what zonules actually do, why pseudoexfoliation ruins your day, and how a viscoelastic-driven pressure spike at 1 AM sent me to clinic to "burp the wound" instead of shipping the patient to the ED. Second, an inpatient consult for suspected optic disc swelling, and why nobody outside ophthalmology reliably examines an optic nerve. Third, the classic infectious disease vs. ophthalmology debate: does every asymptomatic patient with candidemia need a dilated eye exam? IDSA 2016 says yes. The American Academy of Ophthalmology says no. I'll tell you where I actually land and why I still show up anyway. Also: my full case for licensing fireworks rather than banning them, and a little pushback on the once-a-year concern for veterans and dogs. Live shows coming up in Boston and at the Lebanon Opera House in September. Takeaways: Zonule laxity, loose or broken suspensory fibers that hold the natural lens in place, can force a cataract surgeon to abort mid-procedure and refer to a retina specialist for a safer staged approach; pseudoexfoliation is one of the most common causes The viscoelastic gels used during cataract surgery can plug the eye's drainage system and cause an IOP spike that lasts up to 72 hours; oral Diamox is standard, but if the patient can't keep it down, options are IV Diamox in the ED or manually burping the wound in clinic Ophthalmologists are effectively the only clinicians reliably trained and equipped to examine the optic nerve, which is why hospitalist consults for suspected disc swelling should be treated as a normal part of the job, not an imposition The IDSA (2016) recommends dilated exams for all non-neutropenic candidemia patients within one week of diagnosis; the American Academy of Ophthalmology recommends against routine screening in asymptomatic patients. Practical approach for 2026: consult ophthalmology for any candidemia patient with visual symptoms (floaters, blurriness, pain, flashes) or who can't reliably report symptoms (intubated, delirious); asymptomatic reliable patients likely don't need routine screening To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://glaucomflecken.com/glauc-to-me/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you are interested in buying a book from one of our guests, check them all out here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/dr.glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anatomywarehouse.com/?aff=14⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Group A strep in the pediatric ED: from strep throat to invasive disease and toxic shock. Host: Ellen Duncan, MD, PhD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Group_A_Strep.mp3 Download Leave a Comment Tags: Infectious Diseases, Pediatrics Show Notes Background Group A strep = Streptococcus pyogenes — gram-positive organism that colonizes the pharynx, but also the perianal and genital mucosa (worth remembering when the source isn’t the throat). Extremely common. The episode cites an estimated ~289 million cases/yr of strep pharyngitis in children 5–14 (NIH). For a U.S.-specific, verifiable anchor: the CDC estimates strep throat drives ~5.2 million outpatient visits/yr in people

IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, sits down with Past President, Daniel McQuillen, MD, FIDSA, and private practice infectious diseases physician, Sneha Thatipelli, MD, to discuss the value of volunteering with IDSA, finding the right opportunity and how getting involved can shape your career.The 2026 IDSA Call for Volunteers is open now through Friday, July 31. Apply (member login required): https://bit.ly/4gWz6qK

Host Mati Hlatshwayo Davis, MD, MPH, FIDSA is joined by IDSA Senior Vice President of Public Policy and Government Relations Amanda Jezek to discuss the policy challenges shaping infectious diseases, public health and research ahead of the midterm elections. They explore IDSA's advocacy strategy, recent policy wins and how ID professionals can build relationships with policymakers to drive meaningful change.

IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, hosts IDSA board members Ronald Nahass, MD, MHCM, FIDSA, Wendy Armstrong, MD, FIDSA, and Max Brito, MD, MPH, FIDSA, to discuss the challenges and opportunities shaping the field of infectious diseases. From defending vaccine science to strengthening the ID workforce and growing membership, the group shares how IDSA is responding to today's health care challenges and preparing for the future.

Jeff and Jim welcome back five-time guest Jeff Reich, Executive Director of the Identity Defined Security Alliance, just ahead of Identity Management Day 2026 on April 14th. Jeff walks through the structure of the 21-hour global event, this year's theme of Finding Identity: The Search for You, Me, and the Machines, and highlights from each regional program including a remarkable 11th grader presenting on cybersecurity and neuroscience. The conversation expands into AI guardrails, the growing obsolescence of traditional PAM, zero standing privilege as a long-term goal, the march toward a passwordless world through passkeys, and what quantum resilience actually means for practitioners today.Connect with Jeff: https://www.linkedin.com/in/jreich/Learn more about the Identity Defined Security Alliance: https://www.idsalliance.org/Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comTimestamps:00:00 Welcome and podcast life behind the scenes02:00 Identiverse 2026 updates and conference discount codes05:00 Introducing Jeff Reich, Executive Director of IDSA07:00 Identity Management Day: structure of a 21-hour global event11:00 Oceania and Asia region highlights13:30 EMEA highlights and powerhouse panelists from Copenhagen16:00 Americas region and the 11th grader presenting on cybersecurity20:00 Theme reveal: Finding Identity, The Search for You, Me, and the Machines23:30 AI and identity: guardrails, frameworks, and what organizations are missing28:30 Standing privilege is crumbling in the age of ephemeral workloads30:00 Is traditional PAM becoming obsolete?34:30 Zero standing privilege and the passkey journey40:30 Getting the fundamentals right before chasing the shiny tools46:30 Quantum computing, quantum resilience, and cryptocurrency risk53:00 Social engineering is still the biggest threat55:00 Identity Management Day theme song suggestionsKeywords:Identity Management Day 2026, IDSA, Identity Defined Security Alliance, Jeff Reich, IAM, non-human identities, machine identities, agentic identity, zero standing privilege, PAM, passkeys, quantum resilience, AI and identity, deepfakes, social engineering, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Infectologia publicados no Portal Afya.O programa aborda atualizações relevantes sobre tuberculose no Brasil, arboviroses emergentes, manejo de prostatite bacteriana, coinfecção TB-HIV e estratégias no tratamento de infecções por Pseudomonas aeruginosa.Artigos mencionados:Tuberculose no Brasil: o que o infectologista deve saber em 2026?Surto de Febre do Oropouche: estudo compara gravidade e sintomas com a dengueProstatite bacteriana: o que diz a nova revisão da IDSA?Uso de prednisona em pacientes hospitalizados com coinfecção TB-HIVComo manejar infecções difíceis de tratar por Pseudomonas aeruginosa?

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Infectologia publicados no Portal Afya.O programa aborda atualizações relevantes sobre tuberculose no Brasil, arboviroses emergentes, manejo de prostatite bacteriana, coinfecção TB-HIV e estratégias no tratamento de infecções por Pseudomonas aeruginosa.Artigos mencionados:Tuberculose no Brasil: o que o infectologista deve saber em 2026?Surto de Febre do Oropouche: estudo compara gravidade e sintomas com a dengueProstatite bacteriana: o que diz a nova revisão da IDSA?Uso de prednisona em pacientes hospitalizados com coinfecção TB-HIVComo manejar infecções difíceis de tratar por Pseudomonas aeruginosa?

Dr. John Fleetham chats with Dr. Sonal Munsiff and Dr. Raquel Duarte about their article, "Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline." 

Newly appointed IDSA CEO (and former NIAID Director) Jeanne Marrazzo, M.D., M.P.H., joins us this month to discuss a wealth of important topics that stand at the intersection of HIV research, clinical care, and policy/politics. We touch on highlights from the recent CROI 2026 science meeting — both in terms of the research and the vibes; on how the U.S. clinical community must adjust in the wake of cuts to both funding and trust in federal health agencies; on the role of IDSA, HIVMA, and other professional organizations in filling the void; and on the new era that's emerging for clinicians who seek to support their patients and colleagues during a turbulent sociopolitical time.   Read the transcript on TheBodyPro (every click helps!):   https://www.thebodypro.com/podcast/hiv/future-hiv-care-jeanne-marrazzo-croi-march-2026   The host and executive producer of this podcast is Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; and our audio editor is Kim Buikema.

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Pediatria, com foco em anemia ferropriva, aleitamento em prematuros, manejo do derrame pleural e empiema, além de mudanças conceituais no crescimento infantil.Para mais conteúdos como esse, acompanhe nosso canal no Spotify!Leia na íntegra os artigos mencionados hoje:SBP 2026: Recomendações para prevenção e tratamento da anemia ferroprivaAAP atualiza diretrizes sobre aleitamento para RN muito baixo pesoNova diretriz aborda derrame pleural na pneumonia infantil pela IDSA e PIDS – Drenar ou observar?Nova diretriz publicada IDSA e PIDS aborda a conduta no empiemaNova diretriz da AAP e da NASPGHAN exclui o termo “failure to thrive”

Send a textIn this episode of Never Been Sicker, Michael Rubino sits down with Scott Forsgren (Better Health Guy) to unpack what actually helps people recover from complex chronic illness. Scott shares his 30-year journey that began with a tick bite, years of severe symptoms, and 45 doctors before finding answers in Lyme and co-infections, and later, mold exposure.Together, they break down why “kill, kill, kill” protocols often fail, why symptoms overlap across mold, Lyme, metals, and immune dysregulation, and what Scott sees as the true foundations of healing: nervous system regulation, mast cell stability, detox and drainage support, and addressing the external environment.They also dig into controversies around urine mycotoxin testing, ERMI interpretation, and why you may improve while living in exposure, but you typically won't fully recover until the environment is addressed.Chapter markers00:00 Intro00:44 Scott's health story begins (tick bite, sudden symptoms)02:47 First real breakthrough: Lyme and co-infections04:51 What Scott would do differently07:14 Moving beyond “kill, kill, kill”10:03 Can symptoms tell you it's mold?12:20 Why we've never been sicker17:00 Biggest mistakes after diagnosis20:36 The foundational steps to healing34:02 Can you heal while living in exposure?38:33 Urine mycotoxin controversy41:58 ERMI, HERTSMI-2, and interpretation50:04 Mycotoxins, spores, fragments, and why “killing” is not enough56:26 The biggest lie: the label59:28 ILADS vs IDSA and what's true on both sides01:03:02 Where to find Scott + final hope message01:06:10 Outro-----------------------------------------------------------------------------------------------

Canadian energy firm Enbridge will reimburse a northern Wisconsin county for the cost of policing protests expected with construction of the company's Line 5 reroute. As Danielle Kaeding reports, the Ashland County board approved the deal Tuesday. The Wisconsin Counties Association negotiated an agreement where Enbridge will reimburse local governments for public safety costs tied to the Line 5 project in northern Wisconsin. Funds will be deposited into an escrow account managed by the association. Some residents worried the deal would turn local authorities into a private security force. Bad River tribal member Edith Leoso warned against signing the agreement to get reimbursed by Enbridge. “They will feed you what you want to hear, and then they will take everything from this area and leave you to pick up the pieces.” An Enbridge spokesperson said the company volunteered to fund the account. Enbridge also said it received a final US Army Corps permit that the company says will allow construction to move forward, but state approvals for the project are being challenged in court. Enbridge previously paid millions for public safety costs tied to protests of its Line 3 replacement project in Minnesota. ZenniHome founder Bob Worsley shares his excitement about opening up his facility in 2024 atop the former Navajo Generating Station near Page, Ariz. (Photo: Gabriel Pietrorazio / KJZZ) A civil lawsuit filed in Maricopa County Superior Court in Arizona alleges a factory on the Navajo Nation was “squandering millions on improper and mysterious expenditures” before suddenly shutting down in July. KJZZ's Gabriel Pietrorazio has more. The Albuquerque, N.M.-based firm Indigenous Design Studio + Architecture (IDSA) alleges that Mesa subcontractor ZenniHome breached its $50 million deal to build 160 modular homes. “There's a whole lot of money that got dumped into Zenni and obviously only to produce 18 homes, it's a mystery how that occurred.” Attorney Jay Curtis says IDSA is looking to repair the reputation of its founder, Tamarah Begay, in addition to recouping roughly $22 million from the American Rescue Plan Act for the Navajo Nation. ZenniHome CEO Bob Worsley says there will not be a refund of any amount. “No, the money is gone … It's not sitting in somebody's account somewhere, so the company has been liquidated. There's no more assets. It's just almost theater when we spent every dime they gave us, and about $4 million more than that – out of my pocket – so yeah, that's not going to happen.” Worsley also faces a separate federal class action lawsuit after laying off more than 200 employees last year. Rex Lee Jim, Vice President of the Navajo Nation prepares notes prior to a media call in the U.S. Department of Agriculture (USDA) Radio Studio in Washington, D. C., Monday, March. 3, 2015. (Photo: Bob Nichols / USDA) Former Navajo Nation Vice President Rex Lee Jim is being remembered for his advocacy for Navajo people, including in education and culture, and as an international diplomat. Jim served as vice president from 2011 to 2015 with Navajo President Ben Shelly. He also served on the Navajo council, was a poet, playwright, author, and traditional medicine man. The Navajo Nation Council said Jim passed away on Tuesday and recognized his dedication to Navajo people, cultural preservation, and global Indigenous advocacy. JoAnn Chase (Mandan, Hidatsa, and Arikara), former executive director of the National Congress of American Indians (NCAI), is being remembered for strengthening NCAI's national presence and advocating for Native rights. Chase served as executive director from 1994 to 2001. In a statement Tuesday, NCAI said of Chase's passing that her leadership help the organization become stronger and more visible, working with tribal leaders, Congress, and others. She later worked in philanthropy, policy, and arts, including most recently serving as vice chair of the board for the Southwestern Association for Indian Arts. Get National Native News delivered to your inbox daily. Sign up for our daily newsletter today. Download our NV1 Android or iOs App for breaking news alerts. Check out today’s Native America Calling episode Wednesday, February 25, 2026 — The Menu: Commod Bods, a standout frybread stand, and Afro-Indigenous mutual aid in Minneapolis

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. References 1. WHO handbook for guideline development, 2nd Edition, https://www.who.int/publications/i/item/9789241548960 2. The WHO AWaRe (Access, Watch, Reserve) antibiotic book https://www.who.int/publications/i/item/9789240062382 3. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, https://www.idsociety.org/practice-guideline/amr-guidance/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. This episode was edited by Kathryn Hostettler and Lacy Worden. It was peer reviewed for Breakpoints by Lacy Worden and for Communicable by Ljiljana Lukić of University Hospital for Infectious Diseases in Zagreb, Croatia.  References WHO handbook for guideline development, 2nd Edition The WHO AWaRe (Access, Watch, Reserve) antibiotic book IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsFurther readingESCMID AMR Guidelines, https://clinicalmicrobiologyandinfection.com/retrieve/pii/S1198743X21006790 GRADE working group, https://www.gradeworkinggroup.org/GRADE Book, https://book.gradepro.org/ IDSA's intraabdominal guidelines, https://www.idsociety.org/practice-guideline/intra-abdominal-infections/ ESCMID Manual for Clinical Practice Guidelines and Other Guidance Documents, https://www.escmid.org/guidelines-journals/guidelines/ International Consensus Guidelines for the Optimal Use of the Polymyxins https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.2209 American Thoracic Society guidelines on community-acquired pneumonia, https://www.atsjournals.org/doi/abs/10.1164/rccm.202507-1692ST 

Mary Beth Pfeiffer, the pioneering investigative journalist who transformed national understanding of Lyme disease, joins the Tick Boot Camp Podcast for a landmark conversation. Before her work, Lyme disease was widely dismissed as rare, mild, and easily treated. After her reporting, that narrative collapsed. Through her award-winning journalism and her groundbreaking book Lyme: The First Epidemic of Climate Change, she became the first major voice to expose the truth: Lyme disease is a global, climate-driven epidemic that is chronically misdiagnosed, dangerously underestimated, and systematically mishandled by mainstream medicine. In this interview, Mary Beth shares how her earlier investigative work on mental illness in U.S. jails prepared her to recognize patterns of institutional failure within the Lyme disease system. For decades, she documented how people with bipolar disorder and schizophrenia were misunderstood, punished, or dismissed by the very institutions meant to protect them. When she turned her attention to Lyme in 2012, she immediately recognized the same dynamic: patients with neurological and psychiatric manifestations were told they were anxious, depressed, or “crazy,” rather than infected. Families were blamed, symptoms were minimized, and children were left to suffer. Her background gave her a rare lens into how biological illness becomes mislabeled as psychological and how systems silence the very people who need help. Mary Beth explains how her investigative series for the Poughkeepsie Journal went viral worldwide, surprising even her editors. Her reporting was read in all 50 states and across Europe and Australia, prompting the CDC to contact her directly. She details what she uncovered through Freedom of Information Act requests, including internal emails between NIH and CDC officials referring to patients as “Lyme loonies” and framing the situation as a “war” against advocates. These documents revealed attitudes inside the highest levels of public health that shaped decades of policy, diagnostic guidelines, and patient care. The conversation dives into how a small group of early Lyme researchers defined the disease in the 1980s and then used their influence to control medical journals, shape NIH grant funding, and enforce rigid IDSA treatment guidelines. As Mary Beth explains, these early assumptions—often based on limited data and flawed antibody tests—became dogma. Their conclusions created an ecosystem where only short-course antibiotics were considered acceptable, chronic symptoms were dismissed, and doctors who treated beyond the guidelines were punished by medical boards. The result was a generation of patients abandoned by the system, forced to self-fund care, travel to distant specialists, and in many cases bankrupt themselves in search of answers. Mary Beth discusses how patients became her greatest teachers. She shares emotional stories, including children who lost years of their lives, athletes whose careers were derailed, and an 11-year-old boy misdiagnosed for so long he ended up in a hospital bed in his living room before finally being rescued by Dr. Charles Ray Jones. She describes support groups filled with people who had seen five, ten, or fifteen doctors and were told their symptoms were anxiety, depression, or “anything but Lyme.” The interview covers the scientific evidence supporting Lyme persistence, including animal studies, autopsy tissue findings, and molecular research showing Borrelia surviving standard treatment. Mary Beth explains why the two-tier antibody test has failed generations of patients, why indirect antibody tests are inherently flawed for immune-dysregulated populations, and why the future of accurate diagnosis depends on direct detection methods. She highlights emerging technologies, including promising work by Aces Diagnostics and Researcher Holly Ahern, which may finally offer accurate testing across all stages of infection. The conversation moves into the larger systemic problem: how money, insurance policies, medical boards, industry influence, and journal gatekeeping have shaped what doctors are allowed to do. Mary Beth and the Tick Boot Camp team explore why clinicians who try to help chronic Lyme patients often lose insurance coverage, face board complaints, or have their licenses threatened. They discuss how electronic monitoring, AI systems, and corporate-owned medical practices further restrict doctors from practicing individualized, patient-centered medicine. The second half of the interview focuses on the environmental drivers behind the explosion of Lyme disease. Mary Beth explains how warming temperatures, shorter winters, and ecological fragmentation have created ideal habitats for ticks. She describes how ticks have climbed mountains, expanded into higher latitudes, colonized suburban landscapes, and gained longer active seasons. These environmental changes, combined with human development patterns, have dramatically increased opportunities for exposure. She also addresses public interest in the bioweapons question raised by Chris Newby's book Bitten, explaining why historical documentation and FOIA evidence convinced her that military tick experiments occurred, even if their impact on today's epidemic is still unknown. The episode closes with Mary Beth's reflections on prevention, vigilance, and the psychological cost of losing the innocence of nature. She describes how she now sees fields, forests, and even yards differently and why she teaches her grandchildren to treat nature with both respect and caution. She shares her hope for the future: better diagnostics, more independent research, journalists willing to challenge medical orthodoxy, and a cultural shift that frees doctors to practice real medicine rather than rigid algorithms. This interview is essential listening for anyone affected by Lyme disease, anyone questioning why chronic illness is so often dismissed, and anyone seeking to understand how climate change, medical politics, and investigative journalism intersect in one of the most important health crises of our time.

The Interdisciplinary Meeting of Antimicrobial Resistance and Innovation has launched! The first version of IMARI brought together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance" Check the highlights at IMARI.org and prepare for IMARI 2017 from January 27-29, 2027! The inaugural amazing conference took place in Las Vegas. This is the forst time that ASM and IDSA collaborate together in a scientific meeting. One of the sessions involved an unprecedent collaboration between two journals AAC and JID published by each society. To celebrate this achievement we had a session of the best AMR papers of 2025 for AAC and JID. This session will be presented here as apart of our series.  Watch this episode: https://youtu.be/XRYl7863z34 Objectives: - Review the best papers and topics of AMR in 2025 form AAC and JID. - Discuss the context of each finding and contributions to the AMR community - Elaborate on the implications for AMR, novelties and how the field is advancing. Guests:  - Ayesha Khan, Ph.D.  Assistant Professor, Pathology & Laboratory Medicine and Associate Director, Division of Clinical Microbiology Biomedical & Translational Research Track. Principal Investigator, UC3P UCI Prime Pre-Health Pathways Program. - Madison Stellfox, M.D. Ph.D. Assistant Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.  Links:  Links: AAC A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. https://doi.org/10.1128/aac.01627-24 JID Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model https://doi.org/10.1093/infdis/jiaf567 AAC Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors https://doi.org/10.1128/aac.01614-24 JID Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting https://doi.org/10.1093/infdis/jiaf492 AAC Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact https://doi.org/10.1128/aac.00237-25 JID Blood Cultures Contain Populations of Genetically Diverse Candida albicans Strains that May Differ in Echinocandin Tolerance and Fitness https://doi.org/10.1093/infdis/jiaf495 AAC Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains https://doi.org/10.1128/aac.00137-25 JID Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates https://doi.org/10.1093/infdis/jiae438 AAC Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice https://doi.org/10.1128/aac.01310-24 JID The Changing Paradigm in Infectious Diseases—Host-Directed Medicine: Implications for the Next Generation of ID Physicians https://doi.org/10.1093/infdis/jiaf497 JID Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance https://doi.org/10.1093/infdis/jiae239 IMARI Conference This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at https://asm.org/aac.  If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit https://asm.org/joinasm to sign up. Visit https://asm.org/aac to browse issues and/or submit a manuscript. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. 

In this episode of The ICHE Podcast, host Dr. David Calfee speaks with the authors of the newly released Multisociety Guidance for Infection Prevention and Control in Nursing Homes. He is joined by Dr. Lona Mody, Dr. Deborah Burdsall, Dr. Susan Huang, Dr. Robin Jump, and Dr. Rekha Murthy to discuss the development, key updates, and practical implications of this comprehensive guidance. Developed by SHEA in collaboration with APIC, IDSA, PALTmed, and the American Geriatrics Society, the guidance document updates the earlier SHEA/APIC guideline: Infection prevention and control in the long-term care facility published in July 2008. The authors walk through how the updated guidance reflects current evidence and lessons learned, offering a flexible framework to help nursing homes prevent and control infections while preserving the social, rehabilitative, and quality-of-life goals that are central to residential care. Links for this episode: https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/multisociety-guidance-for-infection-prevention-and-control-in-nursing-homes/88B28E99CD7FDB3668DDAE9C3D2184A0

Show notes at pharmacyjoe.com/episode1089 In this episode, I'll discuss a study that addresses the controversy over giving patients with viral infections antibiotics in the Community Acquired Pneumonia guidelines.

Listen in as experts Thomas P. Lodise, PharmD, PhD, and George Sakoulas, MD, FIDSA, explore tailored antibiotic strategies for diverse patients with acute bacterial skin and skin structure infections (ABSSSIs). Their insightful discussion focuses on antibiotic developments that followed publication of the IDSA practice guidelines in 2014 and the challenges unique to ABSSSIs, including a lack of determined bacterial etiology for many cases. PresentersThomas P. Lodise, PharmD, PhDProfessorAlbany College of Pharmacy and Health SciencesInfectious Diseases Clinical Pharmacy SpecialistStratton VA Medical CenterAlbany, New YorkGeorge Sakoulas, MD, FIDSAChief, Infectious DiseasesSharp Rees-Stealy Medical GroupAdjunct Professor of PediatricsUniversity of California San Diego School of MedicineSan Diego, CaliforniaLink to full program:https://bit.ly/4oIKwzsGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Ryan K. Shields, PharmD, MS, in the second of three recap podcasts taken from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients.” Learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:The diverse mechanisms of β-lactam resistanceThe effect of resistance mechanisms on susceptibility to antimicrobials 2024 IDSA guidance for treatmentConsiderations for antibiotic selectionThe role of combination therapyPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:CCO: https://bit.ly/3LXzateProCE: https://bit.ly/3Mjao6GGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Ryan K. Shields, PharmD, MS, in the third of 3 podcasts from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients” to learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:Mechanisms of resistance in S. maltophiliaCurrent frontline therapies2024 IDSA guidance for treatmentPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:https://bit.ly/3JWaqRvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Communicable, Erin McCreary and Angela Huttner are joined by Barbara Trautner (St. Louis, USA) and Valéry Lavergne (Vancouver, Canada), the co-chairs and leading authors of the first IDSA guideline on complicated urinary tract infection (cUTI), which was published a few months ago [1]. Together, they discuss the process of developing the guideline from its conception in 2018, the new definition of cUTI, their stepwise approach to clinical decision-making, and some case-by-case scenarios for common antibiotics. They also elaborate on how this guideline compares (and contrasts) to other existing UTI guidelines—including the previous IDSA guideline for UTI [2] —and the clinical need to supply frontline clinicians to identify and distinguish complicated cases from the uncomplicated ones. The episode closes with what essential clinical questions the guests hope to tackle next.  This episode was edited by Kathryn Hostettler and peer reviewed by Maria Ana Flores of Santa Maria Local Health Unit, Lisbon, Portugal.Other resources:European Urologic Association guidelinesUpToDateFDA guidance on complicated UTI ReferencesTrautner BW, et al. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections Gupta, K, et al. Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update by IDSA

Show notes at pharmacyjoe.com/episode1067. In this episode, I'll discuss recent guidelines about complicated UTI treatment. The post 1067: The IDSA's 4 Step Approach to Choosing Empiric Therapy to Treat Complicated UTI appeared first on Pharmacy Joe.

In this episode of Better Edge, Jennifer Miles-Thomas, MD, moderates a thoughtful conversation with Anthony Schaeffer, MD, discussing complicated urinary tract infections (cUTIs) and their management. Dr. Schaeffer, who contributed to the recent IDSA guidelines on cUTIs, emphasizes the need to understand underlying causes of recurrent infections rather than treating them as isolated events. The conversation explores critical topics such as antibiotic resistance, effective treatment strategies and the importance of early intervention in febrile cases.

About this Episode Episode 49 of “The 2 View” – New IDSA Complicated UTI Guidelines, Pediatric Nicotine OD, Hepatitis C Screening in the ED, High-Risk Delta Troponins Segment 1A – Pediatric Nicotine Ingestion Madelyn O, Hays HL, Kistamgari S, et al. Nicotine Ingestions Among Young Children: 2010–2023. Pediatrics. 2025;156(2):e2024070522. doi:10.1542/peds.2024-070522. Segment 1B – Finger Thoracostomy and Traumatic Pneumothorax/Hemothorax Blank, J, de Moya MA. Traumatic pneumothorax and hemothorax: What you need to know. J Trauma Acute Care Surg. Published online July 3, 2025. doi:10.1097/TA.0000000000004692 Beyer CA, Ruf AC, Alshawi AB, Cannon JW. Management of traumatic pneumothorax and hemothorax. Curr Probl Surg. 2025;63. doi:10.1016/j.cpsurg.2024.101707. Weingart, S. EMCrit 62 – Needle vs. Knife II: Needle Thoracostomy (Decompression)? EMCrit. Published online December 11, 2011. https://emcrit.org/emcrit/needle-finger-thoracostomy/ Lange C, Sharma M. Podcast #223 - ATLS Episode 4: Thoracic Trauma (Chapter 4). Total EM. October 27, 2020. https://www.totalem.org/emergency-professionals/podcast-223-atls-episode-4-thoracic-trauma-chapter-4 Segment 2A – Hepatitis C Screening in EDs Haukoos J, Rothman RE, Galbraith JW, et al. Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial. JAMA. 2025;334(6):497–507. doi:10.1001/jama.2025.10563 Segment 2B – Serial HS-Troponin Patterns Huggins C, Saltarell Ni, Swoboda TK, et al. Kinetic changes in high-sensitivity cardiac troponin for risk stratification of emergency department chest pain patients. Am J Emerg Med. 2025;93:176-181. doi:10.1016/j.ajem.2025.04.010. Segment 3 - Updated IDSA Guidelines on Complicated Urinary Tract Infections Splete H. IDSA Updates Guidelines on Complicated UTIS. Medscape. Published online July 18, 2025. https://www.medscape.com/viewarticle/idsa-updates-guidelines-complicated-utis-2025a1000j3l Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. IDSA. Published online July 17, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/ Roberts M, Sharma M. 34 - Pertussis, Computer Interpretation of EKGs, Tuberculosis, Fluoroquinolone Side Effects. The 2 View. Published online April 10, 2024. https://2view.fireside.fm/34 Roberts M, Sharma M. 46 - Heat Stroke Tx, A New Virus, Oral Cephalosporins Vs Pyelo, Safe Discharges. The 2 View. Published online June 11, 2025. https://2view.fireside.fm/46 Bonus Reference – Ponytail Headache Blau JN. Ponytail Headache: A Pure Extracranial Headache. Headache. 2004;44(5):411-413. doi: 10.1111/j.1526-4610.2004.04092.x. Recurring Sources Center for Medical Education. http://ccme.org The Proceduralist. http://www.theproceduralist.org The Procedural Pause. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. http://www.thesgem.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to.

Have you had symptoms return after stopping Lyme treatment? Share your story below. Your experience may help someone else navigating the same difficult decision.SummaryOne of the most frequent questions in Lyme care is: “If I feel better, should I stop treatment?” The answer is complicated. While no one wants to stay on antibiotics longer than necessary, stopping too soon often leads to relapse.Lyme disease is not a typical infection. Borrelia burgdorferi can persist by hiding in tissues, forming biofilms, and shifting into alternate forms. When treatment ends prematurely, surviving bacteria may re-emerge, and symptoms such as brain fog, joint pain, fatigue, or neuropathy often return. Co-infections like Babesia or Bartonella add another layer, sometimes becoming more obvious once Lyme therapy is withdrawn.Guidelines remain divided. IDSA discourages extended therapy, while ILADS—where I helped author the 2004 and 2014 guidelines—supports individualized, carefully monitored treatment when patients remain ill. The key is shared decision-making, weighing risks and benefits, and avoiding a one-size-fits-all approach.The goal is not indefinite treatment, but the minimum effective therapy that allows patients to heal and reclaim their lives. The takeaway is simple: stopping Lyme treatment too soon often means starting over. Recovery is about staying better tomorrow—not just feeling better today.

“Has your family faced challenges with Lyme disease treatment for kids? Share your story in the comments—because until children are included in research, parents' voices are one of the most powerful tools we have. ..No NIH-funded Lyme treatment trials have included children under 18. Yet kids often present differently than adults—showing fatigue, mood or school changes, rather than joint pain. Their developing immune and nervous systems also process infection and medication uniquely.Because guidelines rely on adult data, children risk being dismissed or undertreated. Some relapse if therapy ends too soon, while others improve only when co-infections are addressed.Bottom line: pediatric Lyme requires individualized, flexible care until research finally includes children...#LymeDisease #LymeTreatment #PediatricLyme #LymeAwareness #ChildHealth #LymeWarrior #ChronicLyme #InvisibleIllness #ParentVoices

Dominate C. diff! Learn to distinguish colonization from infection, select first-line therapies, and counsel patients on recurrence prevention and microbiome recovery. We're joined by IDSA past president and expert on foodborne and intestinal infections, Dr. Cindy Sears (Johns Hopkins University) for a comprehensive update on Clostridioides difficile (C. diff, Cdiff, CDAD, CDI). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 03:00 Guest bio and hobby 04:25 Case of Charles Fleur Fontaine 06:00 Risk factors and epidemiology 08:00 Antibiotic hierarchy of risk 10:00 Diagnosis, testing strategies 14:00 Defining severity 17:30 Treatment options 20:00 Microbiome recovery strategies 24:00 Probiotics and postbiotics 27:00 Infection control counseling 30:00 C. diff and colon cancer 32:00 Recurrent C. diff strategies 35:00 Why some FMT and bezlotoxumab were discontinued 38:00 Microbiota replacement therapies 43:00 Prophylaxis strategies 45:00 Future therapies and ongoing research 47:00 Audience Q&A 52:00 Outro Credits Written and Produced by: Matthew Watto, MD, FACP  Cover Art and Infographic by: Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cynthia Sears MD Disclosures Dr. Sears reports no relevant financial disclosures. Dr. Williams financial relationships disclosed include a Merck grant or research support. This relationship has not ended. Sponsor: Mint Mobile  This year, skip breaking a sweat AND breaking the bank. Get this new customer offer and your 3-month Unlimited wireless plan for just 15 bucks a month at mintmobile.com/CURB  Sponsor: Panacea Financial Let Panacea Financial take the financial stress off your plate,so you can get back to doing what matters most. Visit panaceafinancial.com  Sponsor: FIGS Get15% off your first order at wearfigs.com with the code FIGSRX

She walked away from two decades of luxury bag design to build carbon-negative, vegan bags that actually make a difference. Meet Alona Komsky, co-founder of AKKONIQ, the minimalist bag brand that's reshaping sustainable fashion with innovation, function, and style.In this episode of the Conscious Design Podcast, host Ian Peterman explores how Alona turned her frustration with fast fashion and greenwashing into a mission: designing eco-friendly bags made from 3D-woven recycled materials, biodegradable fibers, and honest minimalist design.If you're interested in ethical fashion, sustainable materials, slow fashion, or how to build a conscious product brand—this episode is for you.⏩ Jump to your favorite parts: 00:52 - Meet Alona Komsky: Co-Founder of Akkoniq01:03 - The Journey to Sustainable Design02:06 - Challenges in the Industry05:00 - Creating Sustainable Bags14:30 - Innovative Materials and Techniques17:10 - Customer Feedback and Education26:38 - The Future of Sustainable Design27:50 - Conclusion and Contact InformationAbout Alona Komsky & AKKONIQAKKONIQ is a new name in sustainable fashion, but co-founder Alona Komsky brings over 20 years of award-winning design experience across tech, travel, and fashion. Her products have won Red Dot, IDSA, and remain global bestsellers.AKKONIQ blends minimalist aesthetics, functional innovation, and planet-first materials. Born from Alona's mission to align design with values, the brand delivers truly sustainable bags—without compromise or greenwashing.

In this episode of The Association Insights Podcast, we continue our July series on sponsorships, partnerships, and non-dues revenue with a behind-the-scenes look at how one major association is building long-term value through strategic partnerships and innovative fulfillment models.Host Meghan Henning sits down with John Buckley, Senior Director of Business Partnerships and Expo Operations at the Infectious Diseases Society of America (IDSA), to explore how IDWeek has evolved into a flagship experience that delivers for both members and industry partners.With nearly 20 years of experience in nonprofit event strategy, John shares how trust, creativity, and a long-game mindset have transformed IDSA's non-dues revenue approach—from tailored sponsorships to citywide visibility campaigns.

A common description of antibiotic action aims to classify them between “bactericidal” or “bacteriostatic”. Although these phenomena have robust in vitro foundations, the clinical translation of these concepts is sometimes difficult to ascertain. This controversial topic has important conceptual ramifications to treat severe infections. Today, we will discuss this topic with an expert in field.  Watch the video version here: https://youtu.be/3z4BItBrzbk Topics discussed: The definitions of “cidal” vs “static” antibiotics The clinical applicability of the above terms in terms of antibiotic choice and syndromatic approaches antibiotic choices and the controversy between bactericidal and bacteriostatic antibiotics.  Guest: Brad Spellberg, MD.  Chief Medical Officer at the Los Angeles General Medical Center  Links: ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026 Watch this session on YouTube This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.  Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Lyme Disease Wars is a term used to acknowledge that theapproach to handling this very serious condition is highly disputed. It's afrustrating subject for me, and I want to share with you some of the realfacts. Today, I'm not talking about pathophysiology. I'm focusing on treatmentand therapy options, and I refer to numerous studies, articles, and other research that you can use the following links to discover for yourself.If you have suffered from Lyme Disease and need more options for recovery, please visit www.laureltreewellnessllc.com to get started.Listed in this episode are the following references:​Medical Gaslighting and Lyme Disease​International Lyme and Associated Diseases Society​Global Lyme Alliance statement on the CDC update​NC Lyme Disease Foundation statement on the CDC update​CDC's current opinion on Chronic Lyme Disease​Article published by Infectious Disease Clinics of North America June 2015 on Chronic Lyme Disease​Frequency of bull's eye rash, as reported by CDC​Article published by IDCNA June 2008​Article by National Institute of Allergy and Infectious Diseases on Lyme Disease November 2018​Lyme Disease in Psychiatry, an article published in Psychiatric Times, 2022.​IDSA's 2025 analysis of clinics offering treatments for Lyme Disease​Time Magazine article on Chronic Lyme Disease, May 2024​John Hopkins study on the effects of Lyme on the brain, 2022​Article about the effects of Lyme on the brain, published in the American Journal of Psychiatry, 1994​Another article by the same author in the same journal, 2021​An article about the relationship of Lyme Disease and Alzheimer's, published in Nature, 2020​Another article about Lyme Disease and Alzheimer's, published in 2022​A PLOS One Journal article about how Lyme Disease impacts the brain, 2020.​Maine taking part in new studies on Lyme Disease

On episode #80 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 4/24/25 – 5/7/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Incidence and Timing of Epstein–Barr Virus Whole Blood DNAemia in Epstein–Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients (Transplant Infectious Disease) Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024 (American Academy of Pediatrics) Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants (Influenza and other respiratory viruses) Hospital admissions of respiratory infections in infants plungewith nirsevimab RSV antibody (CIDRAP) Time to antiviral treatment in mild–moderate COVID-19 in the emergency department (Internal and Emergency Medicine) Delays in COVID antiviral receipt raised risk of poor outcomes after ED visits by 18%, data suggest (CIDRAP) Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV (MMWR) Bacterial Validation and clinical implementation of cerebrospinal fluid C-reactive protein for the diagnosis of bacterial meningitis (LANCET: Regional Health) Bridging to transplant: TDM-Guided Outpatient Dalbavancin Therapy in Chronic Granulomatous Disease with deep-seeded Inoperable Abscesses over 11 Months (OFID) Nitrites for Urinary Tract Infection—Time to Say Goodbye? (JAMA: Internal Medicine) Fungal The Last of US Season 2 (YouTube) High Mortality and Associated Risk Factors in Kidney Transplant Recipients with Cryptococcosis – A Nationwide Cohort Study Over a Decade Using USRDS Data (OFID) Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis (JID) Parasitic Performance of a novel P. falciparum rapid diagnostic test in areas of widespread hrp2/3 gene deletion (CID) Prevalence of Anopheles stephensi in the Horn of Africa: a systematic review and meta-analysis (BMC Infectious Diseases) Raising awareness of Demodex mites: a neglected cause of skin disease (Infection) Miscellaneous Scientific Integrity Under Threat: The Role of the IDSA, PIDS, and SHEA Journals in an Evolving Political Landscape (CID) Reasoning on Rounds Volume 2: a Framework for Teaching Management Reasoning in the Inpatient Setting (Journal of General Internal Medicine) Billing for and documentation of provider-to-provider interprofessional consults in infectious diseases (Journal of the Pediatric Infectious Diseases Society) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In the last decade, there have been major changes in the approach of the treatment of pneumonia, in particular, with the availability of new diagnostic tools. Additionally, new drugs have been approved for the treatment of pneumonia. We discuss the approach to the management of pneumonia with a person who has spent most of his professional career working on this topic. Topics discussed: Definitions and nomenclature of pneumonia and evolution of these terms Changes in the diagnosis of pneumonia Ttherapeutic changes and future approaches for the treatment of pneumonia. Guest: Daniel M Musher, M.D. Links: ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026 This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.  Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Join Jeff and Jim in this episode of the Identity at the Center Podcast as they delve into the upcoming Identity Management Day 2025. Featuring guest Jeff Reich, Executive Director at the Identity Defined Security Alliance (IDSA), this episode unpacks the significance of non-human identities, AI in identity management, and the existential questions surrounding identity. The discussion covers upcoming events, awards, and what to expect from Identity Management Day, while also exploring the potential impact of Quantum Computing. Don't miss out on this in-depth conversation that combines humor with profound insights into the evolving landscape of identity management.Chapters00:00 Introduction and Identity Concerns01:30 AI and Podcasting01:59 AI Limitations and Future05:41 Conference Announcements07:30 Identity Management Day 202509:35 Global Identity Trends18:39 Existential Identity and AI27:29 The Concept of Identity in Technology28:05 Machine Identity and Its Implications29:30 Human vs. Machine Identity31:07 The Future of Identity with AI and Quantum Computing38:13 Identity Management Day Awards45:17 Fun and Lighthearted Discussion51:35 Conclusion and Final ThoughtsConnect with Jeff: https://www.linkedin.com/in/jreich/Learn more about the IDSA: https://www.idsalliance.org/Register for Identity Management Day 2025: https://www.accelevents.com/e/Identity-Management-Day-2025-Virtual-ConferenceConnect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comKeywords: Identity Management, AI, Non-Human Identities, Identity Defined Security Alliance, IDSA, Quantum Computing, Identity Management Day 2025, Identity at the Center Podcast.

Dr. John Fleetham chats with Dr. Sonal Munsiff and Dr. Raquel Duarte about their article, "Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline." 

IT'S A BREAKPOINTS BREAKOUT!Jame and Callum are joined by the drugnamic duo of Julie-Ann Justo & Erin McCreary from the Breakpoints podcast to delve into the IDSA DTR Gram negative Guidance.Show notes for this episode are here.Breakpoints podcast can be found here: https://breakpoints-sidp.org/Lyrics: Tryin' to use some drugs to kill these bugsErin and Julie are PK PD thugs Gonna make these two ID:IOTS look like mugsIt's gonna be a Breakpoints BreakoutSorry the song sounds so tinny, Podcast host is doing something strange to it. Link to original MP3 here. Send us a textSupport the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

On episode #75 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 2/13/25 – 2/26/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral VIMKUNYA (FDA) Co-infection of SARS‐CoV‐2 and influenza A/B among patients with COVID-19(BMC Infectious Diseases) Measles (Texas Health and Human Services) 2025 Measles outbreak guidelines (New Mexico Health) BTN: Beyond the Noise with Paul Offit (microbeTV) Rubeola response (febrile) Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, influenza hospitalization surveillance network (FluSurv-NET), 2012–2019 (CID) Mother-child dyads living with HIV in the Western Cape, South Africa: undetectable = undetectable? (Journal of the International AIDS Society) Early impacts of the PEPFAR stop-work order: a rapid assessment(Journal of the International AIDS Society) Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study (LANCET: Infectious Diseases) Bacterial Effects of extended anaerobic antibiotic coverage on anaerobic bloodstream infection: A multisite retrospective stud (International Journal of Infectious Diseases) The effectiveness of newer Beta-Lactams for the treatment of antimicrobial-resistant gram-negative meningitis (CID) Treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a aeta-analysis of macrolides versus tetracycline (The Pediatric Infectious Disease Journal) Fungal The Last of US Season 2 (YouTube) Concordance of noninvasive plasma cell-free DNA With invasive diagnostics for diagnosis of invasive fungal disease (CID) Invasive fungal infections in patients with liver disease: immunological and clinical considerations for the intensive care unit(Intensive Care Medicine) Parasitic Epidemiologic Investigation of Protozoa and soil-transmitted helminths in Starr County, Texas (American J Trop Med and Hyg) Post-artesunate delayed hemolysis in African children with severe malaria: incidence, medical impact and prevention (CID) Miscellaneous Telehealth (Medicare.gov) Public comment: IDSA guideline on management and treatment of complicated urinary tract infections (IDSA) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In this episode, Martin Witzenrath, MD, FERS, and Michele Bartoletti, MD, PhD, discuss the management of mild to moderate COVID-19 in patients who are immunocompromised, including:Initial workup, which may include laboratory tests and/or imagingLatest data on the use of remdesivir or nirmatrelvir plus ritonavir for mild to moderate COVID-19, including considerations for drug–drug interactions Presenters:Martin Witzenrath, MD, FERSMedical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin FranklinCharite – University of BerlinBerlin, GermanyMichele Bartoletti, MD, PhDAssociate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), Italy Link to full program: https://bit.ly/4gu2gcUDownloadable slides: https://bit.ly/3CGlDBSGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Google agrees to delete billions of user records. NIST addresses the NVD backlog. India rescues hundreds of citizens from scam jobs in Cambodia. The UK and US agree to collaborate on AI safety. The FTC tracks an explosion in impersonation fraud. A PandaBuy breach exposes over 1.3 million customers. Prudential Financial informs over 36,000 customers of a data breach. A look at safeguarding sensitive data. Our guest is Jeff Reich, Executive Director of the Identity Defined Security Alliance (IDSA), with insights on identity security best practices. A dash of curiosity reveals a hotel chain vulnerability.  Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our daily intelligence roundup, Daily Briefing, and you'll never miss a beat. And be sure to follow CyberWire Daily on LinkedIn. CyberWire Guest Guest Jeff Reich, Executive Director of the Identity Defined Security Alliance (IDSA), sharing insights on identity security best practices, identity and access sprawl, and how Generative AI is helping and hurting identity management. The IDSA's Identity Management Day 2024 is coming up on April 9, 2024. Selected Reading Google agreed to erase billions of browser records to settle a class action lawsuit (Security Affairs) Vulnerability database backlog due to increased volume, changes in 'support,' NIST says (The Record) India rescues 250 citizens enslaved by Cambodian cybercrime gang (Bleeping Computer) The US and UK are teaming up to test the safety of AI models (Engadget) Impersonation Scams Net Fraudsters $1.1bn in a Year ( Infosecurity Magazine) PandaBuy data breach allegedly impacted +1.3M customers (Security Affairs) Prudential Financial Data Breach Impacts 36,000 (SecurityWeek) How to bridge the gap between the IT and legal staffs to better combat insider risk (SC Media) IBIS hotel check-in terminal keypad-code leakage (Pentagrid AG) Share your feedback. We want to ensure that you are getting the most out of the podcast. Please take a few minutes to share your thoughts with us by completing our brief listener survey as we continually work to improve the show.  Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at cyberwire@n2k.com to request more info. The CyberWire is a production of N2K Networks, your source for strategic workforce intelligence. © 2023 N2K Networks, Inc.